Single-agent Atezolizumab Improves Survival in PD-L1-High NSCLC

Leggi l'articolo originale


Atezolizumab monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment in patients with wild-type non–small cell lung cancer with PD-L1 expression ≥50%.

Lascia un commento